Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 50 results.
User Information
Export Records
  1. 1.   Molecular replacement with pseudosymmetry and model dissimilarity: a case study
  2. Jaskolski, M.; Li, M.; Laco, G.; Gustchina, A.; Wlodawer, A.
  3. Acta Crystallographica Section D-Biological Crystallography. 2006, FEB; 62(Part 2): 208-215.
  1. 2.   Comparison of the relative efficacies and toxicities of halichondrin B analogues
  2. Alley, M. C.; Smith, A. C.; Donohue, S. J.; Schweikart, K. M.; Newman, D. J.; Tomaszewski, J. E.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9156S-9156S.
  1. 3.   Gene profiling of PXD-101, a novel hydroxamate type inhibitor of histone deacetylase, leads to identification of aurora kinase inhibition
  2. Hose, C.; Shoemaker, R.; Monks, A.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9152S-9152S.
  1. 4.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huan, R.; Wallqvist, A.; Thanki, N.; Covell, D.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9069S-9069S.
  1. 5.   Adaphostin targets Src and Zap-70 in addition to Bcr/abl kinase
  2. Kondapaka, S. B.; Sarangan, R.; Burke, J. R.; Mesner, K. K.; Shoemaker, R. H.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9162S-9162S.
  1. 6.   Ribonucleotide reductase and Cdc7 are important targets of HKH40A, a potent agent against gastrointestinal cancer
  2. Kosakowska-Cholody, T.; Monks, A. P.; Cholody, W. M.; Hariprakasha, H. K.; Kar, S.; Carr, B. I.; Michejda, C. J.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9016S-9016S.
  1. 7.   Proline oxidase, a p53-induced gene, metabolically activates both intrinsic and extrinsic pathways for apoptosis: The role of superoxide radicals, NFAT and MEK/ERK signaling
  2. Liu, Y. M.; Borchert, G.; Surazynski, A.; Hu, C. A. A.; Phang, J. M.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9038S-9038S.
  1. 8.   Targeting topoisomerases to inhibit hypoxia inducible factor 1 (HIF-1): Mechanism and clinical implications
  2. Melillo, G.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9174S-9175S.
  1. 9.   Overview
  2. Michejda, C. J.; Hunt, J. T.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9168S-9168S.
  1. 10.   Preclinical development of halichondrin B and its derivative Eisai E7389
  2. Newman, D. J.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9168S-9168S.
  1. 11.   Topotecan inhibits HIF-1 alpha, but not HIF-2 alpha, protein accumulation and tumor growth in human renal cancer cells
  2. Rapisarda, A.; Uranchimeg, B.; Hollingshead, M.; Borgel, S.; Carter, J.; Shoemaker, R. H.; Melillo, G.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9019S-9019S.
  1. 12.   A novel small molecule activator of CEBPa signaling with anti-leukemic potential identified in a high-throughput screen
  2. Shoemaker, R. H.; Scudiero, D.; Currens, M.; Akee, R.; McCloud, T.; Cardellina, J.; Sausville, E. A.; Radomska, H.; Tenen, D. G.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 8989S-8989S.
  1. 13.   Transmembrane inhibitors of ABCG2, an ABC transporter that confers chemoresistance in cancer stem cells
  2. Tarasova, N. I.; Henrich, C. J.; Amadei, G.; Bokesch, H. R.; Dyba, M. A.; Tarasov, S. G.; McMahon, J. B.; Michejda, C. J.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9052S-9052S.
  1. 14.   Transforming growth factor beta 1 (TGF beta 1) polymorphisms and advanced colorectal adenoma
  2. Berndt, S. I.; Huang, W. Y.; Welch, R.; Chanock, S. J.; Pinsky, P.; Weissfeld, J. L.; Hayes, R. B.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 2 Suppl. S): 2756S-2756S.
  1. 15.   Epidermal expression of the translation inhibitor Pdcd4 suppresses tumorigenesis
  2. Jansen, A. P.; Colburn, N. H.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 2 Suppl. S): 2714S-2715S.
  1. 16.   Identification of celecoxib-modulated proteomic targets in colon cancer cell line, HCT-116
  2. Lou, J. R.; Xiao, Z.; Stauffer, S.; Fatima, N.; Conrads, T.; Veenstra, T.; Greenwald, P.; Ali, I.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 2 Suppl. S): 2750S-2750S.
  1. 17.   Prevention of human papilloma virus (HPV) E7-driven tumorigenesis by dominant negative AP-1 (TAM67) appears to be mediated by Cox-2 repression
  2. Matthews, C. P.; Young, M. R.; Colburn, N. H.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 2 Suppl. S): 2748S-2749S.
  1. 18.   AP-1 blockade in vivo suppresses development of mammary tumor in MMTV-erbB2 mice
  2. Shen, Q.; Kim, H. T.; Young, M.; Gunther, E.; Hilsenbeck, S.; Chodosh, L.; Colburn, N.; Brown, P.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 2 Suppl. S): 2692S-2692S.
  1. 19.   Lsh is involved in de novo methylation of DNA
  2. Zhu, H. M.; Theresa, G. M.; Xi, S. C.; Jiang, Q.; Chen, T. P.; Li, E.; Muegge, K.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 2 Suppl. S): 2686S-2686S.
  1. 20.   Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN
  2. Gao, P.; Wange, R. L.; Zhang, N.; Oppenheim, J. J.; Howard, O. M. Z.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1414-A1415.
  1. 21.   Autoantigens interact with chemokine receptors: Uveitis antigens induce CXCR3 and CXCR5 expressing lymphocytes and immature dendritic cells to migrate
  2. Howard, O. M. Z.; Dong, H. F.; Su, S. B.; Caspi, R. R.; Chen, X.; Plotz, P.; Oppenheim, J. J.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1416-A1416.
  1. 22.   The role of microglial cell FPR2 receptor expression in Alzheimer's disease: Opposing effects of TNFaplha and IL-4 on FPR2 expression
  2. Iribarren, P.; Hu, J. Y.; Chen, K. Q.; Zhou, Y.; Gong, W. H.; Zhang, X.; Wang, J. M.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1418-A1418.
  1. 23.   Cytokine-driven cell cycling is mediated through Cdc25A
  2. Khaled, A. R.; Kittipatarin, C.; Bulavin, D.; Li, W. Q.; Kim, K.; Young, H. A.; Fornace, A.; Durum, S. K.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1415-A1415.
  1. 24.   Toxicity vs antitumor effects of hydrodynamic IL-12 (interleukin-12) and IL-18 cDNA injections
  2. Rodriguez-Galan, M. C.; Watanabe, M.; Young, H. A.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1406-A1406.
  1. 25.   Glutathionylation of cellular proteins induced by a nitric oxide releasing prodrug
  2. Townsend, D.; Findlay, V.; Saavedra, J.; Keefer, L.; Tew, K.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1556-A1556.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel